SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SMS Pharmaceuticals - Quaterly Results

13 Aug 2022 Evaluate
The sales is pegged at Rs. 643.89 millions for the June 2022 quarter. The mentioned figure indicates a decline of about -60.53% as against Rs. 1631.43 millions during the year-ago period.The Net Loss for the quarter ended June 2022 is Rs. -98.06 millions as compared to Net Profit of Rs. 231.98 millions of corresponding quarter ended June 2021Operating Profit reported a sharp decline to 3.76 millions from 457.24 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 643.89 1631.43 -60.53 643.89 1631.43 -60.53 5198.74 5631.78 -7.69
Other Income 8.01 11.44 -29.98 8.01 11.44 -29.98 51.98 34.53 50.54
PBIDT 3.76 457.24 -99.18 3.76 457.24 -99.18 1196.83 1245.63 -3.92
Interest 48.50 49.62 -2.26 48.50 49.62 -2.26 188.75 111.62 69.10
PBDT -44.74 407.62 -110.98 -44.74 407.62 -110.98 1008.08 1134.01 -11.10
Depreciation 79.34 79.95 -0.76 79.34 79.95 -0.76 321.52 222.82 44.30
PBT -124.08 327.67 -137.87 -124.08 327.67 -137.87 686.56 911.19 -24.65
TAX -26.02 95.69 -127.19 -26.02 95.69 -127.19 6.18 301.55 -97.95
Deferred Tax -26.02 25.69 -201.28 -26.02 25.69 -201.28 -143.02 141.09 -201.37
PAT -98.06 231.98 -142.27 -98.06 231.98 -142.27 680.38 609.64 11.60
Equity 84.65 84.65 0.00 84.65 84.65 0.00 84.65 84.65 0.00
PBIDTM(%) 0.58 28.03 -97.92 0.58 28.03 -97.92 23.02 22.12 4.09

SMS Pharmaceuticals Share Price

427.60 3.45 (0.81%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×